These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12433532)

  • 1. The pharmaceutical industry as a political player.
    Abraham J
    Lancet; 2002 Nov; 360(9344):1498-502. PubMed ID: 12433532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
    Griffiths E; Thorpe R; Wadhwa M; Sohn Y
    Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898
    [No Abstract]   [Full Text] [Related]  

  • 4. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical regulation in Greece at the crossroad of change: economic, political and constitutional considerations for a new regulatory paradigm.
    Contiades X; Golna C; Souliotis K
    Health Policy; 2007 Jun; 82(1):116-29. PubMed ID: 17049667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The science and politics of medicines control.
    Abraham J
    Drug Saf; 2003; 26(3):135-43. PubMed ID: 12580644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian government loosens its grip on the pharmaceutical industry.
    Loff B; Cordner S
    Lancet; 2001 Feb; 357(9254):453. PubMed ID: 11273078
    [No Abstract]   [Full Text] [Related]  

  • 8. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fake drugs, what are we talking about? Counterfeit drugs, informal market, quality of pharmaceutical… Thought from an anthropological study led in Benin].
    Baxerres C
    Bull Soc Pathol Exot; 2014 May; 107(2):121-6. PubMed ID: 24639135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry--self-regulation in the shadow of federal prosecution.
    Studdert DM; Mello MM; Brennan TA
    N Engl J Med; 2004 Oct; 351(18):1891-900. PubMed ID: 15509824
    [No Abstract]   [Full Text] [Related]  

  • 11. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 12. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Industrial interests versus public health: the gap is growing.
    Prescrire Int; 2004 Apr; 13(70):71-6. PubMed ID: 15148985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bad execution.
    Nature; 2007 Jun; 447(7145):613-4. PubMed ID: 17554265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
    Davis C; Abraham J
    Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current development in regulation of similar biotherapeutic products in Brazil.
    Castanheira LG; Barbano DB; Rech N
    Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 20. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.